4D Molecular Therapeutics (FDMT) Depreciation & Amortization (CF) (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $1.3 million in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 20.74% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $4.9 million, a 8.41% increase from a year earlier, with the FY2025 full-year figure at $4.7 million, up 0.88% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $1.3 million, up from $1.2 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for FDMT reached as high as $1.3 million in Q1 2026 and fell as low as $406000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $1.0 million across 5 years, with a median of $1.1 million in 2024.
• Across the five-year window, Depreciation & Amortization (CF) jumped 160.0% in 2022 and fell 10.4% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $1.0 million in 2022, then rose by 8.68% to $1.1 million in 2023, then dropped by 0.54% to $1.1 million in 2024, then rose by 10.95% to $1.2 million in 2025, then rose by 4.36% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $1.3 million in Q1 2026, $1.2 million in Q4 2025, and $1.3 million in Q3 2025.